Ulcerative Colitis

AGI said it believes that its AGI-022 drug may offer certain advantages compared with currently marketed therapies, including; a superior tolerability profile, a more reliable and targeted delivery to the affected sites in 'Based on its controlled release profile, it is anticipated that AGI-022 would be dosed twice daily,' the company said.

AGI is now seeking to enter into licensing agreements for AGI-022 with pharmaceutical marketing partners in order to complete development and registration of the product.

Source: Businessworld.ie, March 29 Email to author Article Id: 193768Release date: 29 Mar 2006 About this section , Login Email Password forgotten your password?

Shortcuts A...

Read more...